Entropy Neurodynamics Limited - Asset Resilience Ratio
Entropy Neurodynamics Limited (ENP) has an Asset Resilience Ratio of 70.81% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Entropy Neurodynamics Limited's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Entropy Neurodynamics Limited to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Entropy Neurodynamics Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ENP company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$6.43 Million | 70.81% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$6.43 Million | 70.81% |
Asset Resilience Insights
- Very High Liquidity: Entropy Neurodynamics Limited maintains exceptional liquid asset reserves at 70.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Entropy Neurodynamics Limited Industry Peers by Asset Resilience Ratio
Compare Entropy Neurodynamics Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Entropy Neurodynamics Limited (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Entropy Neurodynamics Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 45.42% | AU$3.03 Million ≈ $2.14 Million |
AU$6.66 Million ≈ $4.71 Million |
-26.64pp |
| 2024-06-30 | 72.06% | AU$5.37 Million ≈ $3.80 Million |
AU$7.45 Million ≈ $5.27 Million |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more